Homozygous Familial Hypercholesterolemia (HoFH) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Homozygous Familial Hypercholesterolemia (HoFH) – Drugs In Development, 2024 report and make more profitable business decisions.
Homozygous familial hypercholesterolemia (HoFH) is a genetic disorder caused by receiving a mutation of the FH gene from both parents. HoFH causes LDL cholesterol level to be very high. Symptoms include xanthelasmas, chest pain, and sores on the toes that do not heal. Treatment includes diet changes and statin drugs.
The Homozygous Familial Hypercholesterolemia (HoFH) drugs in development market research report provide comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Homozygous Familial Hypercholesterolemia (HoFH) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 23 molecules, with 22 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Homozygous Familial Hypercholesterolemia (HoFH) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Homozygous Familial Hypercholesterolemia (HoFH) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Homozygous Familial Hypercholesterolemia (HoFH) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Akeso IncAmgen Inc
Arrowhead Pharmaceuticals Inc
Beijing Mabworks Biotech Co Ltd
Chiesi Farmaceutici SpA
Daewoong Pharmaceutical Co Ltd
Esperion Therapeutics Inc
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
LIB Therapeutics LLC
Lipigon Pharmaceuticals AB
LipimetiX Development Inc
NeuroBo Pharmaceuticals Inc
Novartis AG
PRD Therapeutics Inc
Repair Biotechnologies Inc
Sanofi
Shanghai Junshi Biosciences Co Ltd
Ultragenyx Pharmaceutical Inc
Verve Therapeutics Inc
Vesicle Therapeutics Inc
Visirna Therapeutics HK Ltd
Xi'an Jiaotong University
Table of Contents
Table
Figures
Frequently asked questions